likely to be driven by increased adherence, particularly when compared with active comparators or usual care. The trials were not planned with statistical power to evaluate effects on all-cause mortality and fatal and nonfatal CVD events. Polypills are associated with greater adherence in patients with low baseline adherence compared with patients who already have high adherence. 4 Rather than replace usual care for CVD prevention, polypills will likely be a useful adjunct.
The follow-up period was 12 weeks or less in 6 trials, and 12 to 15 months in the remaining 3 trials. Only 2 trials reported rates of allcause mortality (n = 3465) and fatal and nonfatal CVD events (n = 2479). Two trials included at least 10% of participants with prevalent CVD at baseline.
The intervention group was associated with decreases in systolic blood pressure of 13.4 mm Hg vs 6.3 mm Hg in the comparator group (Table) . The intervention group was associated with a 33.3 mg/dL decrease in mean total cholesterol vs a decrease of 4.3 mg/dL in the comparator group. One secondary prevention trial (n = 2004) reported differences in adherence at 15 months (86% for intervention vs 65% for comparator; relative risk [RR], 1.33 [95% CI, 1.26-1.41]).
The polypill was associated with a higher adverse event rate compared with the comparator group. Seven trials (n = 4864) reported adverse events. Adverse event rates were higher in participants randomized to the polypill compared with comparator (29.7% [739/2485 participants] for polypill vs 24.2% [576/2379] for comparator; RR, 1.19 [95% CI, 1.09-1.30]). The 3 most commonly reported adverse events in the intervention and comparator groups were increased liver chemistries (7.8% for intervention vs 7.6% for comparator, P = .91), cough (6.4% for intervention vs 3.5% for comparator, P = .002), and myalgias (4.0% for intervention vs 3.6% for comparator, P = .55).
All-cause mortality was low in both study groups ( 
Discussion
Polypills are associated with lower blood pressure and cholesterol compared with usual care, active comparators, or placebo, which is CLINICAL QUESTION Is fixed-dose combination therapy (polypill) that combines antiplatelet, blood pressure-lowering, and cholesterol-lowering medications into a single pill associated with improved cardiovascular disease (CVD) risk factors or reduced all-cause mortality or fatal and nonfatal CVD events? Is the polypill associated with an increase in adverse events?
BOTTOM LINE Polypills are associated with greater reductions in systolic blood pressure and total cholesterol compared with usual care, placebo, or active comparators, but also with a 19% higher risk of any adverse event. Due to limited power from available evidence, the association of polypills with all-cause mortality or fatal and nonfatal CVD events is uncertain.
Evidence Profile
No. of randomized clinical trials: 9 trials (7 primary prevention; 2 secondary prevention) Primary outcomes: All-cause mortality; fatal and nonfatal cardiovascular disease events; adverse events Secondary outcomes: Change in total and low-density lipoprotein (LDL) cholesterol concentration, change in systolic and diastolic blood pressure, adherence, health-related quality of life, and costs
